Ozanimod is a sphingosine-1-phosphate (S1PP) receptor modulator that binds with high infinity to S1P subtypes one and five leading to internalization of S1P1 receptors in lymphocytes and the prevention of lymphocyte mobilization to inflammatory sites.
Its use shows significant improvements with regard to endoscopic, histologic, and clinical endpoints in patients with moderate to severe ulcerative colitis.
Similar benefits have been demonstrated in patients with Crohn’s disease.
Adverse events associated with S1P receptor modulation include: bradycardia, serious or opportunistic infections, macular edema and elevated liver enzymes.